Sangamo Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of SGMO for the last quarter is 2.04 M USD, and it's 78.27% lower compared to the previous quarter. The net income of Q4 23 is -60.30 M USD.